BioSpace News Archive

Nearly 1 percent of all children are born with congenital heart disease—a range of potentially life-threatening problems with the structure and function of their hearts.

EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany in the US and Canada, today announced that the European Commission (EC) has approved once-daily oral TEPMETKO® (tepotinib).

US Cancer Antibodies Market, Drug Sales, Patent & Clinical Trials Outlook 2028 Report Highlights.

Fast on the heels of Xoran’s announcement of 900 MiniCAT™ and 50 VetCAT™ installations, we are proud to announce that Xoran has reached 1,000 system installations worldwide,” says Misha Rakic, CEO of Xoran Technologies.

Kala Pharmaceuticals, Inc., announced that the Company granted non-statutory stock options to a new employee as an inducement award outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635.

Sierra Oncology, Inc., a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, granted a stock option to one new employee as approved by the Compensation Committee of the Company’s Board of Directors, under Sierra Oncology’s 2018 Equity Inducement Plan.

BioKansas, the organization that unites, unifies, and promotes the bioscience industry state-wide, is pleased to announce the Innovations in Ag Tech Conference.

Allarity Therapeutics, Inc. (“Allarity” or the “Company”), today announced that the U.S. Food and Drug Administration (“FDA”) has provided the Company with Refusal to File (“RTF”) letters regarding the new drug application (“NDA”) for dovitinib, and its accompanying pre-market approval (“PMA”) application for the DRP®-Dovitinib.

Conformis, Inc., a leading medical device company that features personalized knee and hip replacement products, announced that Mark Augusti, Chief Executive Officer, and Bob Howe, Chief Financial Officer, will participate in three upcoming investor conferences.

Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, and Calyxt, Inc. (“Calyxt”), a majority-owned (61.8% as of December 31, 2021) subsidiary of Cellectis S.A., announced the placement to an institutional investor in an underwritten offering of (i) 3,880,000 shares of Calyxt common stock.